Kestra Medical director gets RSUs, sells 2,932 shares

KMTS director Kevin C. Reilly reported a new RSU grant and a separate nondiscretionary share sale to cover tax withholding on vested awards.

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) director Kevin C. Reilly reported two equity-related transactions. On September 9, 2026, he received 7,217 restricted stock units, each convertible into one common share, which will vest on September 9, 2027, subject to his continued service. On September 8, 2026, he sold 2,932 common shares in a nondiscretionary, sell-to-cover transaction to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units, at a weighted average price of $25.1287 per share.

Insider Trade Summary

Net Seller: 2,932 shares

Net Sell 2 txns

Insider Reilly Kevin C

Role Director

Sold 2,932 shs ($74K)

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F3	7,217	--	--
Sale	Common Shares F1, F2	2,932	$25.1287	$74K

Holdings After Transaction: Common Shares — 12,585 shares (Direct)

Footnotes (3)

1. F1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.3500. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.

Key Figures

Shares sold: 2,932 shares Weighted average sale price: $25.1287 per share RSUs granted: 7,217 units +2 more

5 metrics

Shares sold 2,932 shares Common shares sold on September 8, 2026 in a sell-to-cover transaction

Weighted average sale price $25.1287 per share Average price for 2,932 common shares sold on September 8, 2026; individual prices ranged from $24.91 to $25.35

RSUs granted 7,217 units Restricted stock units granted on September 9, 2026, each for one common share

RSU vesting date September 9, 2027 Vesting date for 7,217 restricted stock units, subject to continued service

Sale price range $24.91 to $25.35 per share Price range for the 2,932 common shares sold on September 8, 2026

Key Terms

restricted stock units, sell to cover, weighted average price, tax withholding obligations

4 terms

restricted stock units financial

"The reported securities represent restricted stock units which each entitle the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"required to be sold by the reporting person pursuant to sell to cover transactions"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"to satisfy tax withholding obligations in connection with the vesting and settlement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did KMTS director Kevin C. Reilly report on this Form 4?

He reported a grant of 7,217 restricted stock units on September 9, 2026, and a sale of 2,932 common shares on September 8, 2026, carried out as a sell-to-cover transaction for tax withholding on vested restricted stock units.

How many Kestra Medical Technologies (KMTS) shares did Kevin C. Reilly sell and at what price?

He sold 2,932 common shares of KMTS on September 8, 2026, at a weighted average price of $25.1287 per share, with individual sale prices ranging from $24.91 to $25.35, as disclosed in the filing’s footnote.

Was Kevin C. Reilly’s KMTS share sale part of a discretionary trade?

No. The filing states the 2,932-share sale was a nondiscretionary sell-to-cover transaction required to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units, rather than a discretionary sale for portfolio reasons.

What are the terms of the 7,217 restricted stock units Reilly received from KMTS?

The filing states the 7,217 reported securities are restricted stock units, each entitling him to one common share of KMTS. These RSUs will vest on September 9, 2027, and vesting is subject to his continued service with the company through that date.

Were Kevin C. Reilly’s KMTS transactions under a Rule 10b5-1 trading plan?

No. The Form 4 indicates no Rule 10b5-1 trading plan for these transactions. The sale is described instead as a required sell-to-cover event to meet tax withholding obligations from restricted stock unit vesting.

Does the Form 4 disclose Kevin C. Reilly’s KMTS share holdings after these transactions?

No. The non-derivative transaction rows report null values for shares owned following the transactions, so post-transaction holdings are not disclosed in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 08:27 PM Accepted by SEC EDGAR 09/10/2026 - 08:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reilly Kevin C

(Last) (First) (Middle)

C/O ALLY BRIDGE GROUP

430 PARK AVENUE 12TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/08/2026		S(1)		2,932	D	$25.1287(2)	5,368	D
Common Shares	09/09/2026		A		7,217(3)	A	(3)	12,585	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.3500. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.

	/s/ Traci S. Umberger as attorney-in-fact for Kevin C. Reilly	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)